dc.contributorKunal, Roy
dc.creatorBellera, Carolina Leticia
dc.creatorSbaraglini, Maria Laura
dc.creatorAlberca, Lucas Nicolás
dc.creatorAlice, Juan Ignacio
dc.creatorTalevi, Alan
dc.date.accessioned2021-12-07T00:40:35Z
dc.date.accessioned2022-10-15T02:59:23Z
dc.date.available2021-12-07T00:40:35Z
dc.date.available2022-10-15T02:59:23Z
dc.date.created2021-12-07T00:40:35Z
dc.date.issued2019
dc.identifierBellera, Carolina Leticia; Sbaraglini, Maria Laura; Alberca, Lucas Nicolás; Alice, Juan Ignacio; Talevi, Alan; In silico modeling of FDA-approved drugs for discovery of therapies against neglected diseases: A drug repurposing approach; Elsevier; 2019; 625-644
dc.identifier978-0-12-816125-8
dc.identifierhttp://hdl.handle.net/11336/148333
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4337633
dc.description.abstractDrug repurposing (i.e., finding new therapeutic uses for already known drugs, including approved, abandoned, discontinued, and investigational drugs) is being extensively applied worldwide to expedite the development of novel therapeutic solutions. Such strategy could be particularly relevant in the fields of neglected and rare diseases, where drug development funding is scarce and most of the ongoing research is funded by the public sector or not-for-profit initiatives. In silico tools can make the drug repurposing approach even more cost-efficient. Here, we present an overview of cheminformatic, bioinformatic, text mining, and network-based approaches that are currently applied to guide drug repurposing, including virtual screening, target fishing, estimation of molecular determinants of promiscuity, binding site similarity predictions, the similarity ensemble approach, among others. Specific applications of such techniques within the field of neglected conditions are discussed, when available.
dc.languageeng
dc.publisherElsevier
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/B9780128161258000213
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/B978-0-12-816125-8.00021-3
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourceIn silico drug design methods for drug repurposing
dc.subjectDRUG REPURPOSING
dc.subjectNEGLECTED DISEASES
dc.subjectIN SILICO MODELING
dc.subjectDRUG DISCOVERY
dc.titleIn silico modeling of FDA-approved drugs for discovery of therapies against neglected diseases: A drug repurposing approach
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typeinfo:eu-repo/semantics/bookPart
dc.typeinfo:ar-repo/semantics/parte de libro


Este ítem pertenece a la siguiente institución